March 22nd 2023
Antibody-drug conjugates, including those targeting PSMA, are among the next wave of treatment advances in mCRPC.
Trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer hits enrollment goal
February 9th 2023"We are very pleased to have reached our recruitment target for the COBRA trial. The data generated thus far on the SAR-bisPSMA product is very encouraging and shows high uptake of the agent by prostate cancer cells,” said Neal Shore, MD.
177Lu-PSMA-617 significantly improves rPFS in earlier mCRPC setting
December 6th 2022According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting.
Potential biomarkers emerge for 177Lu-PSMA-617 in metastatic prostate cancer
November 14th 2022177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.
Expert explains everything you need to know about lutetium Lu-177 vipivotide tetraxetan for mCRPC
October 28th 2022"During treatment with 177Lu-PSMA-617, patients should be counseled to increase oral fluid intake and to void frequently to reduce bladder radiation exposure," writes Stephanie Trexler, PharmD, BCOP.
Urology Times 50 Innovations Series: Multiparametric MRI in prostate cancer
October 5th 2022“From a screening perspective, mpMRI really has changed how we evaluate men at risk for prostate cancer. It has improved the selection of men for biopsy and certainly improved our diagnostic rates,” says William P. Parker, MD.